Parkinson’s Disease Therapeutics: Emphasis on Nanotechnological Advances

PARKINSON’S DISEASE THERAPEUTICS
Copyright
Dedication
Biography
Acknowledgments
1 - Introduction: Parkinson's disease pathology and therapeutics
	1. Introduction
		1.1 Pathology
	2. Micro-ribonucleic acid
	3. Drugs
	4. Viral vectors
		4.1 Nanotechnology
		4.2 Multifarious nanoparticles and surface functionalization
		4.3 Nanoparticles in drug and gene delivery
		4.4 High-density lipoprotein nanoparticles
		4.5 Liposomes
		4.6 Demerits of nanotechnology
	5. Conclusions and future perspectives
	References
	Further reading
2 - Biomaterials: a boon or a bane in the treatment of Parkinson's disease
	1. Introduction
	2. Oxidative stress
	3. Nanoparticles
	4. Neurturin
	5. Delivery systems for natural compounds
	6. Diagnosis
	7. Silver nanoparticles
	8. Immunotherapy
	9. Shortcomings of nanotechnology
	10. Conclusions and future perspectives
	References
	Further reading
3 - Blood-brain barrier targeted nanoparticles
	1. Introduction
		1.1 Physiology
	2. Blood-brain barrier impairment
		2.1 Nanoparticles
		2.2 Cerium oxide nanoparticles
	3. Blood-brain barrier spanning of nanoparticles
	4. Parkinson's disease
	5. Nanoparticles for Parkinson's disease
	6. Gold nanoparticles
	7. Quercetin nanoparticles
	8. Conclusions and future perspectives
	References
	Further reading
4 - Natural compounds in the treatment of Parkinson's disease
	1. Introduction
		1.1 Oxidative stress
	2. Plant-derived compounds
		2.1 Chinese herbs
		2.2 Flavonoids
		2.3 Mitochondria
			2.3.1 Epigallocatechin gallate
		2.4 Silibinin
		2.5 Naringenin
		2.6 Baicalein
		2.7 Polyphenols
		2.8 Polyphenolic flavonoids
			2.8.1 Anthocyanins
	3. Amelioration of antioxidant enzymes
		3.1 Glutathione
		3.2 Metal chelation
	4. Conclusions and future perspectives
	References
5 - Curcumin: a promising therapeutic in Parkinson's disease treatment
	1. Introduction
	2. Antioxidant activity
	3. 6-Hydroxydopamine and MPTP PD models
	4. α-Synuclein targeting
	5. Curcumin derivatives
	6. Bioavailability
	7. Heat shock proteins
	8. Antiapoptosis
	9. Metal chelation
	10. Delivery systems for curcumin
	11. Conclusions and future perspectives
	References
6 - Redox nanoparticles: the corner stones in the development of Parkinson's disease therapeutics
	1. Introduction
	2. Parkinson's disease diagnosis
	3. Coenzyme Q10
		3.1 Nanotechnology
		3.2 Coenzyme Q10 delivery system
		3.3 Nanozyme
		3.4 Dopamine nanoparticles
			3.4.1 Redox-active nanoparticles
			3.4.2 Cerium oxide nanoparticles
	4. Conclusions and future perspectives
	References
7 - Liposomal maneuvers against Parkinson's disease
	1. Introduction
		1.1 Parkinson's disease
	2. Blood-Brain Barrier
	3. Liposomes
	4. Surface functionalization in brain targeting
		4.1 Liposomes in Parkinson's disease
		4.2 Liposomes in dopamine delivery
		4.3 Liposomes for natural compounds
			4.3.1 Curcumin
		4.4 Fibroblast Growth Factor
		4.5 Solid lipid nanoparticles
	5. Demerits of liposomes
	6. Conclusions and future perspectives
	References
	Further reading
8 - Nasal delivery nanoparticles: An insight into novel Parkinson's disease therapeutics
	1. Introduction
	2. Nasal delivery
	3. Challenges in nasal delivery
		3.1 Nanotechnology
		3.2 Liposomes
		3.3 Surface functionalization
		3.4 Chitosan Nanoparticles
		3.5 Nanostructured lipid carriers
		3.6 Peptide-based carriers
		3.7 Polysaccharide-based Nanoparticles
	4. Demerits of nose to brain delivery
	5. Conclusions and future perspectives
	References
	Further reading
9 - α-Synuclein-targeted nanoparticles
	1. Introduction
		1.1 α-Synuclein
	2. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment
	3. Fibrillation
	4. Early diagnosis
		4.1 Therapy
			4.1.1 Nanotechnology
				4.1.1.1 Nanotechnology for Parkinson's disease diagnosis
			4.1.2 Nanotechnology for Parkinson's disease therapy
			4.1.3 Dendrimers
			4.1.4 Curcumin and curcumin-loaded nanoparticles
			4.1.5 Nanoparticles targeted at α-synuclein fibrillation
	5. Conclusions and future perspectives
	References
	Further reading
10 - Pros and cons of Parkinson's disease therapeutics
	1. Introduction
	2. α-Synuclein
	3. Caenorhabditis elegans: a potential animal model for Parkinson's disease
	4. Blood-brain barrier
	5. Stem cell therapy
	6. Influence of gut microbiota on neurodegenerative diseases
		6.1 Nanotechnology
		6.2 Lactoferrin-functionalized nanoparticles
		6.3 Nanotechnology for stem cell therapy
		6.4 Rasagiline-loaded chitosan nanoparticles
		6.5 Dopamine transporting nanoparticles
	7. Conclusions and future perspectives
	References
Index
	A
	B
	C
	D
	E
	F
	G
	H
	I
	K
	L
	M
	N
	O
	P
	Q
	R
	S
	T
	U
	V